Forte Biosciences (FBRX) Liabilities and Shareholders Equity (2016 - 2020)
Forte Biosciences (FBRX) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $22.7 million as the latest value for Q3 2020.
- Quarterly Liabilities and Shareholders Equity fell 67.87% to $22.7 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $69.7 million through Dec 2020, down 73.03% year-over-year, with the annual reading at $7.7 million for FY2019, 92.57% down from the prior year.
- Liabilities and Shareholders Equity for Q3 2020 was $22.7 million at Forte Biosciences, down from $28.3 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $110.8 million in Q2 2017, with the low at $7.7 million in Q4 2019.
- Average Liabilities and Shareholders Equity over 5 years is $66.4 million, with a median of $82.0 million recorded in 2018.
- The sharpest move saw Liabilities and Shareholders Equity surged 160.45% in 2017, then crashed 92.57% in 2019.
- Over 5 years, Liabilities and Shareholders Equity stood at $35.4 million in 2016, then soared by 160.45% to $92.1 million in 2017, then grew by 11.96% to $103.1 million in 2018, then plummeted by 92.57% to $7.7 million in 2019, then surged by 196.81% to $22.7 million in 2020.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $22.7 million, $28.3 million, and $18.6 million for Q3 2020, Q2 2020, and Q1 2020 respectively.